San Diego, California 92161


Purpose:

Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.


Criteria:

Inclusion Criteria: - BMI >30 Exclusion Criteria: - Diabetes Requiring Medication - Poorly Controlled Co-Morbidities


NCT ID:

NCT00546455


Primary Contact:

Principal Investigator
Mario Chojkier, M.D.
University of California, San Diego and San Diego VA Healthcare Medical Center

Monique Gagnon, B.A.
Phone: 858-552-8585 ext. 7216
Email: monique.gagnon@va.gov


Backup Contact:

Email: minocenc@ucsd.edu
Maxine Inocencio
Phone: 858-552-8585 ext. 7216


Location Contact:

San Diego, California 92161
United States

Monique Gagnon, BA
Phone: 858-552-8585
Email: monique.gagnon@va.gov

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 17, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.